Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launch

Lilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within six months of its March launch. The weight-loss and diabetes medication posted ₹80 crore in September sales, surpassing popular brands and attributed to its superior efficacy and first-mover advantage over competitors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VGHjYOt
via IFTTT